-
Thomassen Purcell posted an update 6 months, 3 weeks ago
The mechanical analysis suggested that circVMA21 regulated NRP1 expression through sponging miR-199a-5p.
CircVMA21 upregulation could attenuate LPS-triggered THP-1cell injury through modulating the miR-199a-5p/NRP1 axis, hinting an underlying therapeutic strategy for sepsis patients.
CircVMA21 upregulation could attenuate LPS-triggered THP-1 cell injury through modulating the miR-199a-5p/NRP1 axis, hinting an underlying therapeutic strategy for sepsis patients.Plasmodium falciparum causes the most severe form of malaria. Acquired immunity against P. falciparum provides insufficient protection even after repeated infections. Therefore, P. falciparum parasites might exploit inhibitory receptors for immune evasion. P. falciparum RIFINs are products of a multigene family consisting of 150-200 genes. Previously, we demonstrated that some RIFINs downregulate the immune response through the leukocyte immunoglobulin-like receptor (LILR) family inhibitory receptor, LILRB1, and leukocyte-associated immunoglobulin-like receptor 1, LAIR1. In this study, we further analyzed the expression of inhibitory receptor ligands on P. falciparum-infected erythrocytes and found that P. falciparum-infected erythrocytes expressed ligands for another LILR family inhibitory receptor, LILRB2, that recognizes HLA class I molecules as a host ligand. Furthermore, we identified that a specific RIFIN was a ligand for LILRB2 by using a newly developed RIFIN expression library. In addition, the domain 3 of LILRB2 was involved in RIFIN binding, whereas the domains 1 and 2 of LILRB2 were involved in the binding to HLA class I molecules. These results suggest that inhibitory receptor LILRB2 is also targeted by RIFIN for immune evasion of P. falciparum similar to LILRB1 and LAIR1.Bisphenol A (BPA) and its halogenated analogs tetrabromobisphenol A (TBBPA) and tetrachlorobisphenol A (TCBPA) are common environmental contaminants and a method for their simultaneous determination is urgently needed. A paper-based analytical device (PAD) was prepared using a metal-organic framework of UiO-66-NH2 coated with molecularly imprinted polymers (MIPs) using TBBPA as a template. The maximum adsorption capacity was 120.94 mg g-1 and the imprinting factor was 4.07. The selective recognition ability of this PAD enabled the effective separation of TBBPA, TCBPA and BPA based on paper chromatography. Subsequently, the PAD cut into segments were used individually to determine the presence of target chemicals using a highly sensitive fluorescent method. Under ultraviolet light irradiation, UiO-66-NH2 acts as a photocatalyst to produce reactive oxygen species (ROS) that degrade TBBPA, TCBPA or BPA in the imprinted cavities and the fluorescent signal of 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) added as a ROS probe enabled the indirect determination of target chemicals. This method could determine BPA and its halogenated analogs in dust samples simultaneously with detection limits ranging from 0.14 to 0.30 ng g-1. The intraday relative standard deviation (RSD) was ≤6.8% and interday RSD was ≤8.1%. The recoveries ranged from 91.0 to 105.6% with RSD values that were ≤7.5%. The results stemmed from this method were consistent with those obtained from LC-MS/MS. It is an environmentally-friendly approach due to the degradation of target pollutants and possesses many advantages such as high selectivity, low cost and easy-to-fabrication.Serial measurement of a large panel of protein biomarkers near the bedside could provide a promising pathway to transform the critical care of acutely ill patients. However, attaining the combination of high sensitivity and multiplexity with a short assay turnaround poses a formidable technological challenge. Here, the authors develop a rapid, accurate, and highly multiplexed microfluidic digital immunoassay by incorporating machine learning-based autonomous image analysis. The assay has achieved 12-plexed biomarker detection in sample volume less then 15 μL at concentrations less then 5 pg/mL while only requiring a 5-min assay incubation, allowing for all processes from sampling to result to be completed within 40 min. The assay procedure applies both a spatial-spectral microfluidic encoding scheme and an image data analysis algorithm based on machine learning with a convolutional neural network (CNN) for pre-equilibrated single-molecule protein digital counting. This unique approach remarkably reduces errors facing the high-capacity multiplexing of digital immunoassay at low protein concentrations. Longitudinal data obtained for a panel of 12 serum cytokines in human patients receiving chimeric antigen receptor-T (CAR-T) cell therapy reveals the powerful biomarker profiling capability. The assay could also be deployed for near-real-time immune status monitoring of critically ill COVID-19 patients developing cytokine storm syndrome.Insulin is a high-risk medicine that has been implicated in serious adverse events for hospital inpatients, including medication-error related deaths. Most insulin errors occur during administration, and “wrong dose” is the most common type. NVP-BHG712 A paper-based subcutaneous insulin chart (the “NSIC”) was developed for the Australian Commission on Safety and Quality in Health Care, using a range of human factors methods, with the aim of reducing the opportunity for errors. The present lab-based study empirically assessed whether the NSIC’s human factors design translates into improved user-performance in the determination of insulin doses, compared with a pre-existing chart. Forty-one experienced nurses and 48 novice chart-users completed 60 experimental trials (30 per chart), in which they determined doses to administer to patients. Both groups determined insulin doses faster, and made fewer dose errors, when using the NSIC. These results support the utility of the usability heuristics employed in developing the chart.
To assess the impact of age expansion of screening (EOS) of the target age group from 50 to 69 to 50-74 in Australia, which began mid-2013, by examining screening uptake and outcomes of older women, and by identifying factors associated with continuing screening after reaching the age of 75 years.
Retrospective study using data from women aged 65+ who attended BreastScreen Western Australia between 2010 and 2017 for free mammograms. Screening uptake and screening outcomes were calculated for the periods before (2010-2012) and after (2015-2017) the age EOS to women aged 70-74. Logistic regression was used to identify variables associated with continuing screening after reaching age 75 years, while controlling for possible confounding variables.
Age EOS increased screening uptake amongst women aged 70-74by 36% and amongst women ≥75 years by 3% while screening uptake in women aged 65-69 decreased by 3%. Rate of invasive screened-detected cancers significantly decreased among women aged 70-74 from 11.4/1000 screens before to 8.